GLPwatch

Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?

Prim Care Diabetes · 2021

Last updated 2026-05-28

In clinical trials, a 14 mg dose of oral semaglutide improved blood sugar control by about 1.1% to 1.5% and led to an average weight loss of up to 5 kg over 52 weeks. These results were significantly better than those seen with empagliflozin, sitagliptin, and liraglutide. The most common side effects were mild to moderate stomach issues like nausea, which usually went away over time.

AI summary of the abstract below.

JournalPrim Care Diabetes, 2021
Citations8
Relative citation ratio0.56
NIH percentile32
Molecules semaglutide
Conditions studied Type 2 Diabetes

Abstract

GLP-1 receptor agonists (GLP-1RAs) are recommended for patients with type 2 diabetes (T2D), particularly those at high cardiovascular risk. Oral semaglutide is the first oral GLP-1RA. In clinical trials, oral semaglutide 14 mg reduced mean HbA by approximately 1.1-1.5% and reduced body weight by up to 5 kg. These changes were significantly greater compared with empagliflozin, sitagliptin and liraglutide (p < 0.05 for estimated treatment differences at 52 weeks in patients on treatment without rescue medication use). The most common side effects were gastrointestinal, mainly mild-to-moderate and transient nausea. Oral semaglutide may change the paradigm of T2D treatment in primary care.

Verbatim abstract via PubMed 32826189 ↗

Related research